New Delhi, INDIA, June 26, 2020 : Takeda India, part of the Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, has announced a donation of  1.2 Croresto the PM Cares Fund to support India’s fight against the novel coronavirus disease, COVID-19. The contribution to the PM Cares fund aims to support patients and the government to contain the spread of the disease. Bringing innovative therapies to patients, supporting them through their disease journeys, and playing its part in helping to strengthen healthcare systems is fundamental to Takeda’s operating model, especially in emerging markets like India.

Koki Sato, general manager, Takeda India, commented: “Takeda remains committed to standing together and supporting our communities in India during this unprecedented health crisis.As a company, we have always aimed to operate in-line with our values-Integrity, Honesty, Perseverance, and Fairness- and will therefore never forget that our principal role in society is to serve patients. Together with key authorities and partners we look to addressing some of the world’s most pressing and unmet health challenges, including COVID-19.”

Takeda  has worked with credible NGO partners in the past to support patients and strengthen front-line caregivers through training programs, as part of their corporate social responsibility (CSR) mission. Globally, Takeda works towards preventing disease, training health workers, strengthening supply chains, and improving access to quality diagnosis and treatment. The company actively partners with world-class organizations and NGOs with proven track records to address global health problems in innovative and enduring ways.

Takeda  is part of Takeda Pharmaceutical Company Limited’s group of companies. Locally, the company currently focuses on the areas of Rare Diseases, including Hemophilia and Lysosomal Storage Disorders and plasma-derived therapies. Takeda has a presence across the Indian subcontinent, including in Sri Lanka, Nepal, and Bangladesh.

The post Takeda India contributes Rs 1.2 Crores to COVID-19 PM cares fund appeared first on Health Vision.

New Delhi, INDIA, April 20, 2020: On World Hemophilia Day (April 17), Takeda India, part of Takeda Pharmaceutical Company Limited, a global biopharmaceutical company,pledged to stand united to support patients for a better life and brighter future.Takeda is committed to driving awareness and conversations around Hemophilia to ensure an increased number of diagnoses and, thus, timely treatment with quality replacement therapy.

Koki Sato, General Manager, Takeda India, commented, “As a company, we are committed to serving patients suffering from Hemophilia and support them in their journey to ensure an improved quality of life. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care. With our innovative therapies, awareness drives, and initiatives, we aim to contribute towards building a bleed free India by 2030.”

Through Access to Medicine (AtM) strategy, Takeda aims to address the broader structural barriers that prevent patients in underserved communities from receiving the care and treatment they deserve. In addition to AtM, Takeda India in 2017, launched PurnaSamparq, a patient support program to address the critical unmet needs of Hemophilic patients by offering them Counselling, Diagnostic, Physiotherapy, Nursing and Education Support under the guidance of the Consulting Physician to improve the quality of life.

Gopal Agrawal, Head Market Access, Patient Advocacy, and Patient Services, Takeda India, said “We are committed to addressing the unmet needs of patients wherever they may be, and sustainably strengthening local health systems at every stage of the patient journey. We complement this approach with a commitment towards developing an end-to-end access approach to make our highly-innovative medicines available as soon as practically possible”.

Hemophilia is an inherited single gene disorder that is usually inherited, and about one in every 5,000 males is born with the disorder[2]. As per a reputed patient body in the country, there are approximately 21,000 registered hemophilia patients in India (footnote source). This rare disease mostly impacts pediatric males. While most of the patients opt for on-demand treatment when an episode of bleed occurs, there is prophylaxis treatment that can reduce the annual bleed rate, therefore leading to a reduced lifetime risk of future bleeds and helping the patients to live a better-quality life.

[1] http://www1.wfh.org/publications/files/pdf-1731.pdf.

[2] https://www.hemophilia.in/index.php/hemophilia/about-hemophilia

For more information: https://www.takeda.com

The post Takeda India stands united for Hemophilia appeared first on Health Vision.

The most commonrare diseases identified in Indiaare Haemophilia, Thalassemia, Sickle-cell Anaemia, PrimaryImmunoDeficiency, Lysosomal Storage Disorders such as Gaucher Disease, Fabry Disease, Hunter Syndrome and Pompe’s Disease.[1]

To celebrate Rare Diseases Day, Takeda, aglobal, values-based, R&D-driven biopharmaceutical company pledges to drive increased awareness around rare diseases in India through its Indian entity. The companyis committed to support faster diagnosis and better access to treatments for patients with rare diseases.

Speaking on the occasion of Rare Disease Day, Vineet Singhal, General Manager and Country Head, Takeda India, said “As a company, we are committed to serve patients suffering from rare diseases like Hunter’s syndrome, Gaucher and Fabry and support them in their disease journey to ensure improved quality of life. We intend to leverage and replicate curated initiatives and global best practices in India for the benefit of the patients.”

With a legacy of nearly 239 years, Takeda has established best practices in the rare disease space across the globe.Access to Medicine (AtM)is one such strategy that aims to address the broader structural barriers that prevent patients in underserved communities from receiving the care and treatment they need. The Access to Medicine Foundation and The Access to Medicines Index recognised and ranked Takeda at number five in 2018, where Takeda was also recognised as the biggest upward mover,moving up 10 places to rank number five.[2]

Gopal Agrawal, Head Market Access, Patient Advocacy and Patient Services, Takeda India, says: “As a part of the global community, Takeda has focused its efforts and approach to Access to Medicines (AtM) for the patients suffering with rare diseases. We concentrate our efforts to serve and support the patients through numerous initiatives. We engage with patient bodies, not-for-profit organisations, industry bodies and others to support the interest of patients.”The company believes access to healthcare and medicines should be universal by being accessible and available to the Patients across the country. Takeda is committed to help strengthen the healthcare systems in a sustainable way.

Dr Sandeep Arora, Medical Affairs Head, Takeda India, said: “There are significant unmet medical needs in the management of rare disorders in India, and it is imperative that all stakeholders such as treating physicians, health-care providers, policy-makers and patient groups come together to ensure timely diagnosis and intervention. It is important to raise awareness about the treatable rare diseases so that patients diagnosed with such conditions can access early treatment and have better outcomes. With focus on patients, Takeda runs specific charitable access programs and patient assistance programs to help get access to treatment and ensure they lead near normal lives.”

What is Rare Disease Day?

Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. The campaign targets primarily the general public and seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.

As part of International Rare Disease Day, Takeda globally has launched “Constellation of Rare Stars”to honour patients, families, caregivers, health care professionals and community members who have helped to “Reframe Rare.”

• In India, more than 70-100 million people are suffering from rare diseases, of which treatment options are available for ~450 conditions[1]
• Rare Diseases disproportionately impact children:50% of new cases are in children and are responsible for 35% of deaths before the age of 1 year[1]
• As February 29 is rarest of days, it is marked as the International Rare Disease Day.
• Diagnosis remains the critical challenge for timely intervention

[1]https://mohfw.gov.in/sites/default/files/Rare%20Diseases%20Policy%20FINAL.pdf

[2]https://accesstomedicinefoundation.org/access-to-medicine-index/report-cards/takeda-pharmaceutical-co-ltd

The post Takeda India reaffirms its commitment to Rare disease patients appeared first on Health Vision.